MB-CART20.1
Phase 1Cell therapy
MB-CART20.1 is one of 64 biologic programs targeting Lymphoma. It is currently in Phase 1.
2
Indications
3
Total Trials
1
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Blenoxane
SSequus Pharmaceuticals
Preclinical
Velban
EEastern Cooperative Oncology Group
Preclinical
Oncaspar
SServier
Preclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Preclinical
VP-16
FFundamenta Therapeutics, Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MB-CART20.1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- MMiltenyi Biomedicine GmbH